Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02782663 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
A Phase 2 study of Crohn's Disease (CD), sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 20
- Study locations
NCT02782663 is a Phase 2 study of Crohn's Disease (CD) that has completed, run by AbbVie. The registered enrollment target is 107 participants, below the 180-participant average among 5 other Crohn's Disease (CD) trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02782663, a Phase 2 study of Crohn's Disease (CD), has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
Conditions Studied
Interventions
- DRUG ABT-494
Study Locations (20)
Florida
- Duplicate_University of Florida - Archer /ID# 150033 - Gainesville
- The Ctr for Gastro Disorders /ID# 150012 - Hollywood
- Nature Coast Clinical Research - Inverness /ID# 149975 - Inverness
California
- UC San Diego Health System /ID# 150041 - La Jolla
- Univ California, San Francisco /ID# 149987 - San Francisco
Georgia
- Gastroenterology Associates of Central Georgia, LLC /ID# 149870 - Macon
- GI Specialists of GA, PC /ID# 150015 - Marietta
Maryland
- Investigative Clinical Research /ID# 149886 - Annapolis
- Charm City Research Group /ID# 150040 - Towson
Missouri
- Kansas City Research Institute /ID# 149888 - Kansas City
- Washington University-School of Medicine /ID# 149899 - St Louis
New York
- NYU Langone Long Island Clinical Research Associates /ID# 149976 - Lake Success
- Weill Cornell Medicine/NYP /ID# 149895 - New York
Kansas
- Cotton O'Neil Clinical Research Center, Digestive Health /ID# 149900 - Topeka
Kentucky
- Duplicate_University of Louisville /ID# 149884 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2016-05-18 |
| Est. Completion | 2025-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02782663
The ClinicalTrials.gov registry entry for NCT02782663 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 5 other Crohn's Disease (CD) trials with a reported enrollment target (41% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease (CD) appearing as the primary indexed condition, and to 1 intervention - of which ABT-494 is the first listed.
NCT02782663 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02782663 about?
NCT02782663 is a clinical study titled "A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease". This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
What is the current status of trial NCT02782663?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2016-05-18. Estimated completion is 2025-07-18.
What conditions does trial NCT02782663 study?
This clinical trial studies the following conditions: Crohn's Disease (CD).
What interventions are being tested in trial NCT02782663?
The interventions under investigation include: ABT-494 (DRUG).
Who is sponsoring clinical trial NCT02782663?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02782663 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease (CD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
RECRUITING · NA
-
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
RECRUITING · Phase 3
-
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
ACTIVE NOT RECRUITING · Phase 3
-
Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.